1
|
Gross G, Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol 2013:167-210. [PMID: 23027416 DOI: 10.1007/978-3-642-25758-2_7] [Citation(s) in RCA: 81] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Dopamine D(3) receptors have a pre- and postsynaptic localization in brain stem nuclei, limbic parts of the striatum, and cortex. Their widespread influence on dopamine release, on dopaminergic function, and on several other neurotransmitters makes them attractive targets for therapeutic intervention. The signaling pathways of D(3) receptors are distinct from those of other members of the D(2)-like receptor family. There is increasing evidence that D(3) receptors can form heteromers with dopamine D(1), D(2), and probably other G-protein-coupled receptors. The functional consequences remain to be characterized in more detail but might open new interesting pharmacological insight and opportunities. In terms of behavioral function, D(3) receptors are involved in cognitive, social, and motor functions, as well as in filtering and sensitization processes. Although the role of D(3) receptor blockade for alleviating positive symptoms is still unsettled, selective D(3) receptor antagonism has therapeutic features for schizophrenia and beyond as demonstrated by several animal models: improved cognitive function, emotional processing, executive function, flexibility, and social behavior. D(3) receptor antagonism seems to contribute to atypicality of clinically used antipsychotics by reducing extrapyramidal motor symptoms; has no direct influence on prolactin release; and does not cause anhedonia, weight gain, or metabolic dysfunctions. Unfortunately, clinical data with new, selective D(3) antagonists are still incomplete; their cognitive effects have only been communicated in part. In vitro, virtually all clinically used antipsychotics are not D(2)-selective but also have affinity for D(3) receptors. The exact D(3) receptor occupancies achieved in patients, particularly in cortical areas, are largely unknown, mainly because only nonselective or agonist PET tracers are currently available. It is unlikely that a degree of D(3) receptor antagonism optimal for antipsychotic and cognitive function can be achieved with existing antipsychotics. Therefore, selective D(3) antagonism represents a promising mechanism still to be fully exploited for the treatment of schizophrenia, cognitive deficits in schizophrenia, and comorbid conditions such as substance abuse.
Collapse
Affiliation(s)
- Gerhard Gross
- Abbott, Neuroscience Research, Ludwigshafen, Germany.
| | | |
Collapse
|
2
|
Fliri AF, Loging WT, Thadeio PF, Volkmann RA. Biospectra Analysis: Model Proteome Characterizations for Linking Molecular Structure and Biological Response. J Med Chem 2005; 48:6918-25. [PMID: 16250650 DOI: 10.1021/jm050494g] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Establishing quantitative relationships between molecular structure and broad biological effects has been a long-standing goal in drug discovery. Evaluation of the capacity of molecules to modulate protein functions is a prerequisite for understanding the relationship between molecular structure and in vivo biological response. A particular challenge in these investigations is to derive quantitative measurements of a molecule's functional activity pattern across different proteins. Herein we describe an operationally simple probabilistic structure-activity relationship (SAR) approach, termed biospectra analysis, for identifying agonist and antagonist effect profiles of medicinal agents by using pattern similarity between biological activity spectra (biospectra) of molecules as the determinant. Accordingly, in vitro binding data (percent inhibition values of molecules determined at single high drug concentration in a battery of assays representing a cross section of the proteome) are useful for identifying functional effect profile similarity between medicinal agents. To illustrate this finding, the relationship between biospectra similarity of 24 molecules, identified by hierarchical clustering of a 1567 molecule dataset as being most closely aligned with the neurotransmitter dopamine, and their agonist or antagonist properties was probed. Distinguishing the results described in this study from those obtained with affinity-based methods, the observed association between biospectra and biological response profile similarity remains intact even upon removal of putative drug targets from the dataset (four dopaminergic [D1/D2/D3/D4] and two adrenergic [alpha1 and alpha2] receptors). These findings indicate that biospectra analysis provides an unbiased new tool for forecasting structure-response relationships and for translating broad biological effect information into chemical structure design.
Collapse
Affiliation(s)
- Anton F Fliri
- Pfizer Global Research and Development, Groton, CT 06340, USA.
| | | | | | | |
Collapse
|
3
|
Sumida K, Walf AA, Frye CA. Progestin-facilitated lordosis of hamsters may involve dopamine-like type 1 receptors in the ventral tegmental area. Behav Brain Res 2005; 161:1-7. [PMID: 15904704 DOI: 10.1016/j.bbr.2005.02.013] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2004] [Accepted: 02/17/2005] [Indexed: 10/25/2022]
Abstract
Hamsters are highly-dependent upon the central actions of progesterone (P) to facilitate sexual behavior. P has membrane mechanisms of action in the ventral tegmental area (VTA) to facilitate sexual receptivity of rodents. The present experiments examined whether P's membrane actions in the VTA include dopamine (DA) type 1 (D(1)) or dopamine type 2 (D(2)) receptors. Ovariectomized (ovx), estradiol (E(2))- and P-primed hamsters were infused with D(1) (Experiment 1) or D(2) (Experiment 2) antagonists or agonists (0 or 100 ng) to the VTA and tested 30 min later. The D(1) agonist, SKF38393, enhanced P-facilitated lordosis. The D(1) antagonist, SCH23390, attenuated P-facilitated lordosis. The D(2) agonist, quinpirole and the D(2) antagonist, sulpiride, had no significant effects on P-facilitated lordosis. These data suggest that, in hamsters, P's actions for lordosis may involve D(1) receptors in the VTA.
Collapse
Affiliation(s)
- Kanako Sumida
- Department of Psychology, The University at Albany-SUNY, Albany, NY 12222, USA
| | | | | |
Collapse
|
4
|
Frye CA, Walf AA, Sumida K. Progestins' actions in the VTA to facilitate lordosis involve dopamine-like type 1 and 2 receptors. Pharmacol Biochem Behav 2005; 78:405-18. [PMID: 15251249 DOI: 10.1016/j.pbb.2004.04.014] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/10/2004] [Revised: 03/29/2004] [Accepted: 04/09/2004] [Indexed: 10/26/2022]
Abstract
In the ventral tegmental area (VTA), 5alpha-pregnan-3alpha-ol-20-one (3alpha,5alpha-THP) facilitates lordosis. Whether this involves dopamine type 1 (D1) or dopamine type 2 (D2) receptors is of interest. Ovariectomized (ovx) rats with guide cannulae to the VTA were estradiol (E2) primed and pretested for lordosis. Rats were then infused with the D1 (Experiment 1) or D2 (Experiment 2) antagonists or agonists (0, 100, or 200 ng) to the VTA and were retested. After a second infusion of 3alpha,5alpha-THP (0, 100, or 200 ng) or vehicle, rats were tested 10, 60, and 120 min later. In Experiment 3, rats were administered a progestin receptor antagonist, RU38486, systemically or to the VTA 1 h prior to vehicle, SKF38393 and/or 3alpha,5alpha-THP infusions. 3alpha,5alpha-THP infusions increased lordosis over that seen with E2 priming. The D1 antagonist, SCH23390, attenuated 3alpha,5alpha-THP, but not E2-facilitated lordosis. The D1 agonist, SKF38393, augmented 3alpha,5alpha-THP, but not E2-facilitated lordosis. The D2 antagonist, sulpiride, had no significant effects on lordosis. The D2 agonist, quinpirole, prevented 3alpha,5alpha-THP-facilitated lordosis. RU38486 (subcutaneous) inhibited lordosis, whereas infusions to the VTA decreased lordosis produced by SKF38393 and 3alpha,5alpha-THP, but not 3alpha,5alpha-THP alone. Thus, 3alpha,5alpha-THP's actions in the VTA for lordosis may involve D1 and/or D2 receptors.
Collapse
Affiliation(s)
- Cheryl A Frye
- Department of Psychology, The University at Albany-SUNY, Albany, NY 12222, USA.
| | | | | |
Collapse
|
5
|
Yamada S, Harano M, Tanaka M. Antagonistic effects of beta-phenylethylamine on quinpirole- and (-)-sulpiride-induced changes in evoked dopamine release from rat striatal slices. Eur J Pharmacol 1998; 343:145-50. [PMID: 9570461 DOI: 10.1016/s0014-2999(97)01529-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
To assess the role of beta-phenylethylamine in aspects of dopamine release, we measured the level of beta-phenylethylamine in the rat striatum after killing the rats by microwave irradiation. We then investigated the effect of beta-phenylethylamine on electrically evoked dopamine release from rat striatal slices in vitro. The striatal beta-phenylethylamine level was 46.5 +/- 3.5 ng/g wet tissue, equivalent to 0.3 micromol/l. Superfusion with low concentrations of beta-phenylethylamine up to 1 micromol/l had no effect on spontaneous or electrically evoked dopamine release from striatal slices. Quinpirole reduced the evoked dopamine release from slices in a concentration-dependent manner. The quinpirole-induced reduction of evoked dopamine release was attenuated 30% by superfusion with 0.3 micromol/l beta-phenylethylamine. Moreover, the (-)-sulpiride (0.1 micromol/l)-induced increase in evoked dopamine release was also attenuated by superfusion with 0.3 micromol/l beta-phenylethylamine. These data indicate that submicromolar levels of beta-phenylethylamine could modify the dopamine autoreceptor mediated changes in evoked dopamine release from rat striatal slices.
Collapse
Affiliation(s)
- S Yamada
- Institute of Brain Diseases, School of Medicine, Kurume University, Fukuoka, Japan.
| | | | | |
Collapse
|
6
|
Yavich L, Lappalainen R, Sirviö J, Haapalinna A, MacDonald E. Alpha2-adrenergic control of dopamine overflow and metabolism in mouse striatum. Eur J Pharmacol 1997; 339:113-9. [PMID: 9473124 DOI: 10.1016/s0014-2999(97)01375-7] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The effects of the alpha2-adrenoceptor drugs, medetomidine and atipamezole, on dopamine overflow evoked by low (6 Hz-10 s) and high (50 Hz-4 s) frequency electrical stimulation of the median forebrain bundle were studied in striatum of BALB/C mice anaesthetized with chloral hydrate with fast in vivo voltammetry techniques. The effects of these drugs on the basal concentrations of dopamine metabolites were also investigated by means of differential pulse voltammetry. Medetomidine dose dependently decreased dopamine overflow in nucleus accumbens in the dose range 5-100 microg/kg, s.c. This effect was seen only at low frequency stimulation and reached 85% at a dose of 100 microg/kg. Medetomidine also decreased the basal concentration of striatal homovanillic acid. This effect did not exceed 35%. Atipamezole antagonized the inhibitory effects of medetomidine on the dopamine overflow. but showed no effect itself. We suggest that alpha2-adrenoceptors in dopaminergic terminal fields in the mouse striatum are involved in the regulation of dopamine release at physiological stimulation frequencies.
Collapse
Affiliation(s)
- L Yavich
- Department of Pharmacology and Toxicology, University of Kuopio, Finland.
| | | | | | | | | |
Collapse
|
7
|
Harsing LG, Zigmond MJ. Influence of dopamine on GABA release in striatum: evidence for D1-D2 interactions and non-synaptic influences. Neuroscience 1997; 77:419-29. [PMID: 9472401 DOI: 10.1016/s0306-4522(96)00475-7] [Citation(s) in RCA: 101] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Striatal slices from the rat were preincubated with [3H]GABA and superfused in the presence of nipecotic acid and aminooxyacetic acid, inhibitors of high-affinity GABA transport and GABA aminotransferase, respectively. GABA efflux was estimated by monitoring tritium efflux, 98% of which was in the form of [3H]GABA. The following three major observations were made: (1) The overflow of GABA evoked by electrical field stimulation (8 Hz) was increased two-fold by SKF-38393 (10 microM), an agonist at the D1 family of dopamine receptors. This increase was completely blocked by the D1 receptor antagonist SCH-23390 (10 microM). However, SCH-23390 had no effect on GABA overflow when given alone. Thus, dopamine agonists appear to exert an excitatory influence on GABA release; however, this effect was not elicited by endogenous dopamine under the conditions of this experiment. (2) Electrically evoked GABA overflow was reduced 50% by quinpirole (10 microM), an agonist at the D2 family of dopamine receptors, and this effect was blocked by the D2 antagonist sulpiride (10 microM). Moreover, exposure to sulpiride alone caused a 60% increase in GABA overflow, and this effect was abolished by 3-iodotyrosine (2 mM), a dopamine synthesis inhibitor. Thus, D2 agonists appear to exert an inhibitory influence on dopamine release, an effect that can be exerted by endogenous stores of dopamine. (3) The stimulatory effect of SKF-38393 was attenuated by quinpirole, whereas the sulpiride-induced increase in GABA efflux was attenuated by SCH-23390. Sulpiride also increased [3H]GABA efflux during KCl-induced depolarization, an effect that was antagonized by SCH-23390 as in the case of electrical stimulation. However, although tetrodotoxin did not alter the stimulatory effect of sulpiride, it did block the ability of SCH-23390 to antagonize the sulpiride-induced increase in GABA overflow. These latter results suggest that there is an interaction between D1 and D2 receptors whereby the effects of dopamine mediated via D1 sites are inhibited by an action on D2 sites. In conclusion, our results suggest that (i) dopamine agonists can exert an excitatory influence on depolarization-induced GABA release within neostriatum via D1 receptors and an inhibitory influence via D2 receptors; (ii) under the conditions of these experiments, endogenous dopamine fails to act on D1 sites but does exert an inhibitory influence via D2 sites; and (iii) there is an interaction between D1 and D2 receptors such that the actions of dopamine mediated via D1 sites are inhibited as a result of the concomitant actions exerted via D2 sites.
Collapse
Affiliation(s)
- L G Harsing
- Department of Neuroscience, University of Pittsburgh, PA 15260, USA
| | | |
Collapse
|
8
|
Yamada S, Harano M, Yokoo H, Tanaka M. Antagonistic effects of OPC-14597, a novel antipsychotic drug, on quinpirole- and (-)-sulpiride-induced changes in evoked dopamine release in rat striatal slices. J Pharm Pharmacol 1997; 49:206-8. [PMID: 9055196 DOI: 10.1111/j.2042-7158.1997.tb06780.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The effects of a newly synthesized quinolinone derivative, 7-[4-(4-(2,3-dichlorophenyl)-1-piperazinyl) butoxy)-3,4-dihydro-2-(1H)-quinolinone (OPC-14597), a novel antipsychotic drug, on electrically evoked dopamine release in rat striatal slices were investigated. OPC-14597 (0.1-10 microM) had no effect on the dopamine release evoked in the striatal slices. The decrease induced by quinpirole, a dopamine receptor agonist, in evoked dopamine release was attenuated by superfusion with OPC-14597 (1 and 10 microM) which by itself had no effect on evoked dopamine release. The increase induced by (-)-sulpiride, a dopamine receptor antagonist, in evoked dopamine release was, moreover, also attenuated by 1 and 10 microM OPC-14597. These findings indicate that OPC-14597 antagonizes both dopamine agonist- and antagonist-induced changes in evoked dopamine release in striatal slices in rats.
Collapse
Affiliation(s)
- S Yamada
- Institute of Brain Diseases, Kurume University School of Medicine, Fukuoka, Japan
| | | | | | | |
Collapse
|
9
|
Ries V, Hertting G, Jackisch R. Properties of 3,4-diaminopyridine-evoked dopamine and acetylcholine release in rabbit caudate nucleus slices: involvement of facilitatory adenosine A2 receptors or nitric oxide? Brain Res 1996; 743:303-14. [PMID: 9017259 DOI: 10.1016/s0006-8993(96)01102-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The 3H-overflow from slices of the rabbit caudate nucleus preincubated with tritiated dopamine (DA), or choline, and then superfused and stimulated twice with 3,4-diaminopyridine (3,4-DAP; 25 microM, 1 min), was explored as an in vitro model for evoked release of DA, or acetylcholine (ACh), respectively. In both cases the 3,4-DAP-evoked 3H-overflow was tetrodotoxin-sensitive and Ca(2+)-dependent and hence most probably represents action potential-induced exocytotic release of DA or ACh, respectively. Using pairs of preferential agonists/antagonists it was shown, that evoked DA release was inhibited via presynaptic D2 autoreceptors (quinpirole/domperidone) and kappa-opioid receptors (U-50488H/norbinaltorphimine). No evidence was found for the presence of presynaptic adenosine A1 or A2 receptors on dopaminergic terminals. Moreover, 3,4-DAP-evoked DA release was unaffected by increased intracellular cyclic AMP levels or by drugs affecting the NO/guanylate cyclase pathway. In a similar manner it was shown that 3,4-DAP-evoked ACh release was inhibited via presynaptic muscarine autoreceptors (oxotremorine/atropine) and dopamine D2 heteroreceptors (quinpirole/domperidone). Again, no evidence for the involvement of the NO/guanylate cyclase system in the modulation of ACh release was found, whereas the presence of inhibitory adenosine A1 receptors, but not of facilitatory A2 receptors, could be clearly established. It is concluded, that 3,4-DAP-evoked 3H-overflow from rabbit caudate nucleus slices preincubated with [3H]DA or [3H]choline, represents a simple and useful in vitro model for action potential-induced DA or ACh release, respectively. Moreover, at least in this model or rabbit brain region, facilitatory adenosine A2 receptors and the NO/guanylate cyclase system seem not to be involved in the release of these transmitters.
Collapse
Affiliation(s)
- V Ries
- Institute of Pharmacology, University of Freiburg, Germany
| | | | | |
Collapse
|
10
|
Markstein R, Gull P, Rüdeberg C, Urwyler S, Jaton AL, McAllister K, Dixon AK, Hoyer D. SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity. J Neural Transm (Vienna) 1996; 103:261-76. [PMID: 8739838 DOI: 10.1007/bf01271238] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
SDZ PSD 958, a novel benzo[g]quinoxaline derivative exhibits the properties of a potent orally active selective D1 receptor antagonist. It has high affinity for D1-like receptors (D1, D5; pKi = 9.7-9.8) labelled by [3H]SCH23390 and is at least 400 fold less active at D2-like receptors (i.e. D2, D4) labelled by [3H]spiperone. Effects in functional tests are consistent with D1 receptor antagonist properties. SDZ PSD 958 inhibited apomorphine-induced rearing in mice and prevented prolongation of novelty-induced locomotion in rats elicited by the selective D1 receptor agonist CY 208-243. By contrast, SDZ PSD 958 did not induce catalepsy and only weakly inhibited apomorphine-induced stereotyped gnawing in rats. This suggests that SDZ PSD 958 preferentially inhibits responses mediated by dopamine systems innervating the limbic system.
Collapse
|
11
|
Markstein R, Gull P, Rüdeberg C, Urwyler S, Jaton AL, Kalkman HO, Dixon AK, Hoyer D. SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors. J Neural Transm (Vienna) 1996; 103:17-30. [PMID: 9026371 DOI: 10.1007/bf01292613] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
SDZ GLC-756, a novel octahydrobenzo[g]quinoline derivative, is equipotent in displacing [3H]SCH23390 from dopamine D1 receptors and [3H]205-501 from dopamine D2 receptor binding sites. It blocks dopamine sensitive adenylate cyclase with the same potency as SCH23390, indicating antagonist properties at dopamine D1 receptors. On the other hand, SDZ GLC 756 inhibits electrically evoked acetylcholine release from rat striatal slices with the same potency as the selective dopamine D2 receptor agonist bromocriptine. This effect is blocked by spiperone suggesting that it is mediated by dopamine D2 receptor activation. The opposing action of SDZ GLC 756 on dopamine D1 and D2 receptors is also evident in vivo. SDZ GLC 756, like SCH23390, blocks apomorphine-induced rearing in mice. On the other hand, it inhibits prolactin secretion and produces circling in unilateral 6-OHDA-lesioned rats, which is compatible with stimulant properties at dopamine D2 receptors. This drug might be a new tool to study linkage between dopamine D1 and D2 receptors.
Collapse
Affiliation(s)
- R Markstein
- Preclinical Research, Sandoz Pharma Ltd., Basle, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Bo P, Soragna D, Marchioni E, Candeloro E, Albergati A, Savoldi F. Role of dopamine D-1 and D-2 antagonists in a model of focal epilepsy induced by electrical stimulation of hippocampus and amygdala in the rabbit. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19:917-30. [PMID: 8539428 DOI: 10.1016/0278-5846(95)00120-k] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
1. The differential role played by blockade of D-1 or D-2 dopamine receptors in mechanisms underlying seizures was studied in a model of EEG after-discharge induced by electrical stimulation of selective brain regions (dorsal hippocampus and amygdala) in the rabbit. 2. The D-2 antagonist haloperidol (1 mg/Kg) increased significantly after-discharge duration after stimulation of either hippocampus or amygdala and lowered after-discharge threshold in few animals. 3. The D-1 antagonist SCH 23390 (0.3 mg/Kg) caused no changes following stimulation of amygdala and reduced after-discharge duration when hippocampus was stimulated. 4. Haloperidol exerted a proconvulsant action in this experimental model, having a clearer influence on D-2 receptors. SCH 23390 had no effect on amygdala whereas it exerted protection on the hippocampus. 5. The present data suggest that D-1 and D-2 receptors have different roles in generating and spreading the epileptic activity.
Collapse
Affiliation(s)
- P Bo
- Neurological Institute C. Mondino Pavia, Italy
| | | | | | | | | | | |
Collapse
|
13
|
Yamada S, Takaki T, Yokoo H, Tanaka M. Differential effects of dopamine antagonists on evoked dopamine release from slices of striatum and nucleus accumbens in rats. J Pharm Pharmacol 1995; 47:259-62. [PMID: 7602493 DOI: 10.1111/j.2042-7158.1995.tb05791.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The effects of dopamine-receptor antagonists on electrically-evoked dopamine release were compared in the nucleus accumbens and striatal slices of rats. (-)-Sulpiride induced a concentration-dependent increase in the evoked dopamine release from both regions, the increase in the nucleus accumbens being significantly greater than that in the striatum. Clozapine also increased evoked dopamine release from the nucleus accumbens, but not from the striatum. The haloperidol-induced increase in evoked dopamine release from the nucleus accumbens was less than that from the striatum. These findings indicate that, in terms of dopamine transmission, (-)-sulpiride and clozapine, but not haloperidol, predominantly affect the nucleus accumbens rather than the striatum. We have previously reported that the contribution of D3 receptors to the regulation of dopamine release from dopamine nerve terminals is much greater in the nucleus accumbens than that in the striatum. (-)-Sulpiride and clozapine have relatively higher affinity for D3 receptors than does haloperidol. The regional differences in responsiveness of dopamine release to dopamine antagonists could be due to the different affinities to D2 or D3 receptors of the dopamine antagonists.
Collapse
Affiliation(s)
- S Yamada
- Institute of Brain Diseases, Kurume University School of Medicine, Japan
| | | | | | | |
Collapse
|
14
|
Heal DJ, Czudek C, Buckett WR. Common profile of D1 receptor antagonists and atypical antipsychotic drugs revealed by analysis of dopamine turnover. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18:803-21. [PMID: 7938568 DOI: 10.1016/0278-5846(94)90086-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
1. Selective antagonists of dopamine D1 and D2 receptors enhanced 3-methoxytyramine (3-MT) accumulation in the striata and accumbens of tranylcypromine pretreated rats. Selective D1 and D2 agonists produced opposite effects. The smaller changes produced by the D1 agonists and antagonists were probably mediated by neuronal feedback, whereas the larger effects produced by the D2 ligands predominantly reflected pharmacological actions at prejunctional dopaminergic autoreceptors. 2. Atypical antipsychotics evoked small increases in 3-MT similar to the effects of the selective D1 inhibitors, whereas the mixed D1/D2 antagonists mimicked the selective D2 inhibitors by inducing much larger elevations in 3-MT. 3. gamma-Butyrolactone, an inhibitor of dopaminergic neuronal firing, dose-dependently decreased 3-MT accumulation in both the striata and accumbens. 4. gamma-Butyrolactone pretreatment abolished the small increases in 3-MT induced by the selective D1 antagonists and the atypical antipsychotics and also the large increases produced by the mixed D1/D2 antagonists. By contrast, gamma-butyrolactone only partially reversed the marked elevation of 3-MT evoked by the selective D2 antagonists. 5. The above data suggest that in vivo the atypical antipsychotics behave predominantly as selective D1 antagonists.
Collapse
Affiliation(s)
- D J Heal
- Boots Pharmaceuticals Research Department, Nottingham, UK
| | | | | |
Collapse
|
15
|
Yamada S, Yokoo H, Nishi S. Differential effects of dopamine agonists on evoked dopamine release from slices of striatum and nucleus accumbens in rats. Brain Res 1994; 648:176-9. [PMID: 7922522 DOI: 10.1016/0006-8993(94)91920-8] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The effects of dopamine receptor agonists on electrically evoked dopamine release from slices of nucleus accumbens were compared with the effects on release from striatal slices in rats. Apomorphine, which has equal potency at the dopamine D2 and D3 receptors, reduced the evoked dopamine release from both regions to the same extent (ED50, 0.42 microM for nucleus accumbens; ED50, 0.46 microM for striatum). Quinpirole or 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OHDPAT), which are much more potent at the D3 receptor than at the D2 receptor, reduced the evoked dopamine release from the nucleus accumbens (ED50, 0.12 microM for quinpirole; 0.02 microM for 7-OHDPAT) much more than the release from the striatum (ED50, 1.6 microM for quinpirole; 0.55 microM for 7-OHDPAT). These results suggest that the contribution of D3 receptors in nucleus accumbens to regulate dopamine release from dopamine nerve terminals is much greater than in striatum.
Collapse
Affiliation(s)
- S Yamada
- Institute of Brain Diseases, Kurume University School of Medicine, Japan
| | | | | |
Collapse
|
16
|
Seyfried CA, Adam G. Studies on the interaction of roxindole with brain monoamine oxidases and dopaminergic neurones in vitro and in vivo. PHARMACOLOGY & TOXICOLOGY 1994; 74:314-20. [PMID: 7937563 DOI: 10.1111/j.1600-0773.1994.tb01366.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Roxindole, a structurally novel psychotropic indolylbutyl-4-phenyltetrahydropyridine, was studied with respect to the formation of potentially neurotoxic pyridinium metabolites in comparison to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). In contrast to MPTP, roxindole failed to serve as a substrate for monoamine oxidases (MAO) from mouse, monkey and human brain in vitro. Accordingly, neither the putative MAO-oxidation product of roxindole (ROX+) nor MPP+ (1-methyl-4-phenylpyridinium ion) was detected in mouse striatum after high subcutaneous doses of roxindole in spite of the presence of approximately 6 micrograms of roxindole per g of striatum in these animals. After multiple subcutaneous treatments with 95.2 mg/kg roxindole, no long-term striatal dopamine depletions were observed in contrast to MPTP. Furthermore, unlike MPP+, ROX+ did not induce release of previously accumulated 3H-dopamine in mouse striatal slices indicating that ROX+ cannot utilize the dopamine uptake carrier to enter neurones. ROX+ at doses up to 100 mg/kg subcutaneously failed to alter striatal biogenic amine levels and gross behaviour of mice. Thus, no MPTP-like neurotoxic metabolites are formed from roxindole in vivo and neurotoxic effects of ROX+, even if formed in minute amounts by some MAO-independent pathway, are highly unlikely.
Collapse
Affiliation(s)
- C A Seyfried
- Department of CNS Research, E. Merck, Darmstadt, Germany
| | | |
Collapse
|
17
|
Jackson DM, Westlind-Danielsson A. Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol Ther 1994; 64:291-370. [PMID: 7878079 DOI: 10.1016/0163-7258(94)90041-8] [Citation(s) in RCA: 319] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The description of new dopamine (DA) receptor subtypes, D1-(D1 and D5) and D2-like (D2A, D2B, D3, D4), has given an impetus to DA research. While selective agonists and antagonists are not generally available yet, the receptor distribution in the brain suggests that they could be new targets for drug development. Binding characteristics and second messenger coupling has been explored in cell lines expressing the new cloned receptors. The absence of selective ligands has meant that in vivo studies have lagged behind. However, progress has been made in understanding the function of DA-containing discrete brain nuclei and the functional consequence of the DA's interaction with other neurotransmitters. This review explores some of the latest advances in these various areas.
Collapse
Affiliation(s)
- D M Jackson
- Department of Behavioural, Pharmacology, Astra Arcus AB, Södertälje, Sweden
| | | |
Collapse
|
18
|
Fedele E, Andrioli GC, Ruelle A, Raiteri M. Release-regulating dopamine autoreceptors in human cerebral cortex. Br J Pharmacol 1993; 110:20-2. [PMID: 8106101 PMCID: PMC2176017 DOI: 10.1111/j.1476-5381.1993.tb13765.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Slices from fresh specimens of human neocortex which had to be removed during neurosurgery to reach subcortical tumours were labelled with [3H]-dopamine and stimulated electrically. Quinpirole, a selective dopamine D2 receptor agonist, inhibited the stimulated tritium overflow (EC50 = 25 nM; maximal inhibition: about 80% at 10 microM). The selective D1 receptor agonist, SKF 38393, was inactive up to 10 microM. Quinpirole was antagonized by the D2 receptor antagonist (-)-sulpiride (apparent pA2 = 8.26). Thus dopaminergic axon terminals in the human mesocortical pathway possess autoreceptors of the D2 type.
Collapse
MESH Headings
- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology
- Adult
- Cerebral Cortex/metabolism
- Cerebral Cortex/physiology
- Dopamine/metabolism
- Dopamine Agents/pharmacology
- Electric Stimulation
- Ergolines/pharmacology
- Female
- Humans
- In Vitro Techniques
- Male
- Middle Aged
- Quinpirole
- Receptors, Dopamine/drug effects
- Receptors, Dopamine/metabolism
- Receptors, Dopamine D1/drug effects
- Receptors, Dopamine D1/metabolism
- Receptors, Dopamine D2/drug effects
- Receptors, Dopamine D2/metabolism
- Sulpiride/pharmacology
Collapse
Affiliation(s)
- E Fedele
- Institute of Pharmacology and Pharmacognosy, University of Genova, Italy
| | | | | | | |
Collapse
|
19
|
Gifford AN, Johnson KM. A pharmacological analysis of the effects of (+)-AJ 76 and (+)-UH 232 at release regulating pre- and postsynaptic dopamine receptors. Eur J Pharmacol 1993; 237:169-75. [PMID: 8103459 DOI: 10.1016/0014-2999(93)90265-j] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
To examine the proposal that (+)-AJ 76 and (+)-UH 232 are dopamine receptor antagonists showing preference for the dopamine autoreceptors over postsynaptic dopamine receptors, the potencies of these two compounds, as well as several typical and atypical antipsychotic drugs, were compared in a model for presynaptic dopamine autoreceptors: reversal of the quinpirole-induced inhibition of [3H]dopamine release from striatal slices, and in two models for postsynaptic dopamine receptors: reversal of the quinpirole-induced inhibition of [14C]acetylcholine release from striatal slices and competition for [3H]spiperone binding in striatal homogenates. The IC50 values of the antipsychotic drugs, as well as (+)-AJ 76 and (+)-UH 232, against [3H]dopamine release correlated closely with their IC50 values against [14C]acetylcholine release and Ki values against [3H]spiperone binding, thus suggesting a close pharmacological similarity between these three populations of dopamine receptors. This implies that previous biochemical and behavioral findings obtained with (+)-AJ 76 and (+)-UH 232 cannot be explained by a selective action of these compounds on terminal dopamine autoreceptors regulating dopamine release, at least relative to the postsynaptic dopamine receptors on cholinergic neurons. Furthermore, comparison of the IC50 values for the drugs tested in our transmitter release assays with previously published values of their affinity for cloned dopamine D2, D3 and D4 receptors suggested that the dopamine receptors controlling both dopamine and acetylcholine release were by far most similar to dopamine D2 receptors.
Collapse
Affiliation(s)
- A N Gifford
- Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston 77555-1031
| | | |
Collapse
|
20
|
Yamada S, Yokoo H, Nishi S. Modulation of (-)-sulpiride-induced increase in electrically-evoked release of dopamine from rat striatal slices. J Pharm Pharmacol 1993; 45:479-81. [PMID: 8099971 DOI: 10.1111/j.2042-7158.1993.tb05580.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
(-)-Sulpiride (10 nM-10 microM) in the superfusate, dose-dependently increased the electrically-evoked release of dopamine from rat striatal slices. (+)-Sulpiride had little effect on evoked release of dopamine up to 10 microM. Apomorphine inhibited electrically evoked release of dopamine, and this effect of apomorphine was antagonized by (-)-sulpiride. SCH23390 and forskolin had no effect on the (-)-sulpiride-induced increase in evoked release of dopamine. Treatment with the irreversible dopamine-receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline caused a significant increase in evoked release of dopamine and prevented the (-)-sulpiride-induced increase in the evoked release of dopamine. These results indicate that the (-)-sulpiride-induced increase in evoked release of dopamine is due to antagonism of the activation of dopamine autoreceptors by endogenously released dopamine.
Collapse
Affiliation(s)
- S Yamada
- Institute of Brain Diseases, Kurume University School of Medicine, Japan
| | | | | |
Collapse
|
21
|
Dolezal V, Jackisch R, Hertting G, Allgaier C. Activation of dopamine D1 receptors does not affect D2 receptor-mediated inhibition of acetylcholine release in rabbit striatum. Naunyn Schmiedebergs Arch Pharmacol 1992; 345:16-20. [PMID: 1347152 DOI: 10.1007/bf00175463] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The possible involvement of dopamine D1 receptors in the regulation of acetylcholine release in the rabbit caudate nucleus was investigated. Caudate slices, preincubated with [3H]choline, were superfused continuously and subjected to electrical field stimulation with only a single pulse. In agreement with the view that the release of acetylcholine evoked by a single electrical pulse is not influenced by endogenous transmitters, atropine and domperidone failed to increase the evoked release of [3H]acetylcholine, whereas oxotremorine and quinpirole caused a concentration-dependent inhibition of transmitter release. Neither the dopamine D1 receptor antagonist SCH 23390 nor the D1 agonist SKF 38393 in a concentration range of 0.01-1 mumol/l changed the evoked [3H]acetylcholine release. The inhibitory effect of the dopamine D2 receptor agonist quinpirole was virtually abolished in the presence of 0.1 mumol/l domperidone and diminished in the presence of 1 mumol/l SCH 23390. It remained unchanged in the presence of 1 mumol/l SKF 38393. It is concluded that the inhibition of acetylcholine release by dopamine is mediated exclusively via presynaptic dopamine D2 receptors and that the antagonistic effect of SCH 23390 on the inhibition of acetylcholine release by quinpirole is due to its interaction with dopamine D2 rather than D1 receptors located on cholinergic nerve terminals.
Collapse
Affiliation(s)
- V Dolezal
- Institute of Physiology, Czechoslovak Academy of Sciences, Prague
| | | | | | | |
Collapse
|
22
|
POSTER COMMUNICATIONS. Br J Pharmacol 1992. [DOI: 10.1111/j.1476-5381.1992.tb14730.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
23
|
Hashimoto T, Katsura M, Kuriyama K. On the mechanism of mergocryptine-induced suppression of dopamine turnover in the rat striatum. Eur J Pharmacol 1991; 198:121-7. [PMID: 1864302 DOI: 10.1016/0014-2999(91)90610-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The effect of mergocryptine, a new ergot alkaloid, on the cerebral dopaminergic systems was examined using Wistar rats. The administration of mergocryptine (1 and 10 mg/kg i.p.) induced a significant suppression of striatal dopamine (DA) turnover. In vitro addition of mergocryptine (0.01-100 microM) induced a dose-dependent suppression of the release of [3H]DA from striatal slices. Mergocryptine inhibited [3H]apomorphine binding to a striatal synaptosomal fraction, and its IC50 value was found to be 0.23 microM. Pretreatment with apomorphine (100 micrograms/kg s.c.) showed an additive effect on the mergocryptine (10 mg/kg)-induced suppression of DA turnover. These results suggest that mergocryptine may induce the suppression of striatal DA turnover by reducing DA release via the stimulation of presynaptic dopaminergic autoreceptors.
Collapse
Affiliation(s)
- T Hashimoto
- Department of Pharmacology, Kyoto Prefectural University of Medicine, Japan
| | | | | |
Collapse
|
24
|
Ferrari F, Claudi F. Behavioural evidence for central D-2 dopamine receptor agonistic effect by some 2-(fluorohydroxyphenyl)ethylamines. Pharmacol Biochem Behav 1991; 38:131-4. [PMID: 2017441 DOI: 10.1016/0091-3057(91)90600-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The IP injection of 2-(4-fluoro-3-hydroxyphenyl)ethylamines. (FDA 24), N-n-propyl-N-(2-phenylethyl)-2-(3-fluoro-4-hydroxyphenyl)ethylamine (FDA 27F) and N-n-propyl-N-(2-phenylethyl)-2-(4-fluoro-3-hydroxyphenyl) ethylamine (FDA 40) into adult male rats induced the stretching and yawning (SY) syndrome, FDA 24 being the least active. Moreover, FDA 27F and FDA 40 potentiated penile erection (PE) with respect to controls. For both signs (PE and SY), FDA 40 was the most potent of the three compounds. These effects, which are considered typical signs of central D-2-dopamine (DA) receptor stimulation, were dose-related and significantly inhibited by pretreatment with the selective D-2 DA antagonist, sulpiride, but not by domperidone, which does not cross the hematoencephalic barrier. In previous binding studies, FDA 27F and FDA 40 showed high affinity and selectivity for D-2 DA receptors, while FDA 24 had a low affinity for both D-1 and D-2 DA receptors. The present data show that FDA 27F and FDA 40 cross the blood-brain barrier and exert an agonistic effect on the central D-2 DA receptors. These results also provide evidence of the value of PE and SY tests as sensitive tools for the study of DA-neurochemical mechanisms.
Collapse
Affiliation(s)
- F Ferrari
- Institute of Pharmacology, University of Modena, Italy
| | | |
Collapse
|
25
|
Suaud-Chagny MF, Ponec J, Gonon F. Presynaptic autoinhibition of the electrically evoked dopamine release studied in the rat olfactory tubercle by in vivo electrochemistry. Neuroscience 1991; 45:641-52. [PMID: 1775239 DOI: 10.1016/0306-4522(91)90277-u] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Evoked dopamine release was monitored in vivo from the olfactory tubercle of anaesthetized rats by differential pulse amperometry combined with carbon fibre electrodes which, in most cases, were electrochemically treated. Dopamine release was evoked by electrical stimulation of the ascending dopaminergic pathway. The dopamine release evoked by burst stimulation (20 s with a mean frequency of 6 Hz) was dose-dependently decreased by D,L-apomorphine (25-800 micrograms/kg, s.c.) or by quinpirole (50 micrograms/kg, s.c.) while the opposite effect was observed with haloperidol (12.5 micrograms/kg-0.5 mg/kg, s.c.) or with D,L-sulpiride (2-200 mg/kg, s.c.). Neither the D1 agonist SKF 38393 (10 mg/kg, s.c.) nor the D1 antagonist SCH 23390 (0.5 mg/kg, s.c.) affected the evoked dopamine release. Moreover, sulpiride competitively antagonized the effects of apomorphine. The relative amplitude of the apomorphine inhibition was inversely correlated with the stimulation frequency (6 or 9 Hz). The increase induced either by haloperidol or by sulpiride was positively related to the stimulation frequency (from 3 to 9 Hz) and reached a stable value (+700% of the pre-drug-evoked dopamine release) with higher frequencies (from 9 to 20 Hz). This increase also depended on the duration of the stimulation: both single-train (10 pulses) or burst stimulations for 20 s, whose frequency inside the trains was in both cases 14 Hz, evoked a dopamine release which was minimally affected by sulpiride or haloperidol. In conclusion, in physiological conditions the amplitude of the impulse flow-dependent dopamine release is regulated by the extrasynaptic extracellular dopamine concentration which varies from 10 to 100 nM. This presynaptic autoinhibition is mediated by autoreceptors of the D2 type and is involved in the nonlinear relationship between impulse flow and dopamine release.
Collapse
Affiliation(s)
- M F Suaud-Chagny
- INSERM U 171, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
| | | | | |
Collapse
|
26
|
Drukarch B, Schepens E, Dolleman-Van der Weel MJ, De Boer P, Van Vliet BJ, Stoof JC. Lack of a dopamine autoreceptor selective profile of B-HT 920 in functional in vitro model systems of D2 receptors in rat striatum. Eur J Pharmacol 1990; 187:257-69. [PMID: 1980248 DOI: 10.1016/0014-2999(90)90012-u] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Based on the results of in vivo studies, the thiazoloazepine derivative B-HT 920 has been proposed to be a selective agonist of dopamine autoreceptors. In the present study, we investigated the effects of B-HT 920 in two functional in vitro model systems of D2 receptors and compared these effects with the effects of the classical D2 agonist LY 171555. B-HT 920 and LY 171555 concentration dependently inhibited the electrically evoked release of radiolabeled dopamine and acetylcholine and the forskolin-induced stimulation of adenylate cyclase activity in rat striatal tissue slices with comparable efficacies. In striatal tissue slices prepared after 6-hydroxydopamine-induced destruction of dopaminergic terminals, both drugs were still able to inhibit forskolin-stimulated adenylate cyclase activity with a efficacy similar to that in tissue obtained from unlesioned rats. It is concluded that, in vitro, B-HT 920 is an agonist at both presynaptic and 'normosensitive' postsynaptic D2 receptors showing relatively high intrinsic activity.
Collapse
Affiliation(s)
- B Drukarch
- Department of Neurology, Medical Faculty, Free University, Amsterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
27
|
Andersen PH, Gingrich JA, Bates MD, Dearry A, Falardeau P, Senogles SE, Caron MG. Dopamine receptor subtypes: beyond the D1/D2 classification. Trends Pharmacol Sci 1990; 11:231-6. [PMID: 2200181 DOI: 10.1016/0165-6147(90)90249-8] [Citation(s) in RCA: 214] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The D1/D2 dopamine receptor classification is widely accepted. However, intense investigative efforts over the last several years using pharmacological, biochemical and behavioral approaches have produced results that are increasingly difficult to reconcile with the existence of only two dopamine receptor subtypes. Recent developments, including cloning of the cDNAs and/or genes for several members of the large family of G-protein-coupled receptors, have revealed that heterogeneity in the pharmacological or biochemical characteristics of individual receptors often indicates the presence of previously unsuspected molecular subtypes. In this article, Marc Caron and colleagues have assembled the main lines of evidence that suggest the presence of several novel subtypes for both D1 and D2 dopamine receptors and predict that molecular cloning will, in the near future, confirm their existence.
Collapse
Affiliation(s)
- P H Andersen
- Novo Nordisk A/S, CNS Division, Bagsvaerd, Denmark
| | | | | | | | | | | | | |
Collapse
|
28
|
Barnes JM, Barnes NM, Costall B, Naylor RJ. The actions of (-)N-n-propylnorapomorphine and selective dopamine D1 and D2 receptor agonists to modify the release of [3H]dopamine from the rat nucleus accumbens. Neuropharmacology 1990; 29:327-36. [PMID: 1971430 DOI: 10.1016/0028-3908(90)90090-e] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The ability of (-)N-n-propylnorapomorphine and selective D1 and D2 dopamine receptor agonists and antagonists to modify the release of [3H]dopamine, induced by potassium from the nucleus accumbens, was studied using an in vitro superfusion technique. (-)N-n-Propylnorapomorphine, in picomolar concentrations, inhibited the release of [3H]dopamine, the inhibition being antagonised by fluphenazine and the selective D2 receptor antagonist sulpiride; the selective D1 receptor antagonist SCH 23390 was ineffective. The selective D1 receptor agonist SKF 38393 and the selective D2 agonist quinpirole, both inhibited the potassium-induced release of [3H]dopamine; no synergistic effect was observed to a combined treatment with SKF 38393 and quinpirole. The effects of SKF 38393 and quinpirole were selectively antagonised by SCH 23390 and sulpiride, respectively, although both antagonists failed to modify the release of [3H]dopamine when administered alone. Receptor antagonists for other transmitter sites, e.g. noradrenaline, 5-hydroxytryptamine and acetylcholine, failed to modify potassium-induced release of [3H]dopamine, when administered alone or to prevent the inhibition of the release caused by (-)N-n-propylnorapomorphine. It is concluded that the action of dopamine agonists on both dopamine D1 and D2 receptors in the nucleus accumbens can reduce the release of [3H]dopamine in the in vitro system. Comparable actions in vivo may contribute to the ability of dopamine agonists to moderate locomotor responding.
Collapse
Affiliation(s)
- J M Barnes
- Postgraduate Studies in Pharmacology, School of Pharmacy, University of Bradford U.K
| | | | | | | |
Collapse
|
29
|
Palij P, Bull DR, Sheehan MJ, Millar J, Stamford J, Kruk ZL, Humphrey PP. Presynaptic regulation of dopamine release in corpus striatum monitored in vitro in real time by fast cyclic voltammetry. Brain Res 1990; 509:172-4. [PMID: 2137719 DOI: 10.1016/0006-8993(90)90329-a] [Citation(s) in RCA: 86] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Dopamine release was evoked by single electrical pulses in slices of rat corpus striatum, and measured by fast cyclic voltammetry in real time. The magnitude of the release varied in the expected way to agents which modify dopamine storage, release and re-uptake. The presence of functional dopamine D2 autoreceptors was demonstrated by showing that the release was potently and completely inhibited by the selective agonists quinpirole and N,N-dipropyl-5,6-ADTN. The selective D1 agonist SKF 38393 was ineffective. The inhibition by quinpirole was competitively antagonised by haloperidol and metoclopramide with potencies which correspond closely to published values at postsynaptic striatal D2 receptors. Thus, the D2 autoreceptors on striatal nerve terminals appear to be indistinguishable from those on the postsynaptic neurons.
Collapse
Affiliation(s)
- P Palij
- Department of Neuropharmacology, Glaxo Group Research Ltd., Ware, U.K
| | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
The catecholamine dopamine plays an important role as a neurotransmitter or neurohormone in the brain and pituitary gland. Dopamine exerts its effects through activation of two types of receptors called D-1 and D-2. These receptors are distinguished by their different pharmacological characteristics and signal transduction mechanism(s). Release of dopamine inhibits the activity of dopaminergic neurons through activation of so-called dopamine autoreceptors which are of the D-2 type. In general, these receptors occur both in the soma-dendritic region of the dopaminergic neuron, where they are involved in the inhibition of the firing rate and on the dopaminergic terminals where they mediate the inhibition of dopamine synthesis and release. D-2 receptors occur also on the target cells of dopaminergic neurons both in the brain (postsynaptic D-2 receptors) and pituitary gland. On the basis of data gathered from in vivo (behavioral- as well as electrophysiological) studies it has been concluded that D-2 agonists are much more potent at dopamine autoreceptors as compared to postsynaptic D-2 receptors, indicating the possibility of a pharmacological distinction between these differentially located D-2 receptors. This concept led to the introduction of a whole group of drugs allegedly displaying a selective agonist profile at the dopamine autoreceptor. In contrast, biochemical (in vitro) studies with brain tissue as well as the pituitary gland, did not reveal any significant difference between the pharmacological profiles of autoreceptors and postsynaptic D-2 receptors. In the present minireview a balanced discussion is presented of these in vivo and in vitro findings and it is concluded that both autoreceptors as well as postsynaptic D-2 receptors are similar if not identical entities.
Collapse
Affiliation(s)
- B Drukarch
- Department of Neurology, Medical Faculty, Free University, Amsterdam, The Netherlands
| | | |
Collapse
|
31
|
Arbuthnott GW, Fairbrother IS, Butcher SP. Dopamine release and metabolism in the rat striatum: an analysis by 'in vivo' brain microdialysis. Pharmacol Ther 1990; 48:281-93. [PMID: 2128125 DOI: 10.1016/0163-7258(90)90050-c] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Brain microdialysis studies on the mechanisms underlying dopamine release in the rat striatum provide evidence that both exocytotic and carrier-dependent processes operate in vivo. While several releasers (potassium, veratrine, amphetamine, ouabain) utilize newly synthesized stores of dopamine, tyramine is uniquely sensitive to depletion of vesicular storage by reserpine. Extracellular DOPAC is closely associated with the newly synthesized pool of dopamine and experiments with selective monoamine oxidase inhibitors suggest that DOPAC is formed mainly by MAO-A. Recent work on the two dopamine receptors suggest that release by different mechanisms may selectively activate D1 or D2 receptor subtypes.
Collapse
Affiliation(s)
- G W Arbuthnott
- Department of Preclinical Veterinary Sciences, University of Edinburgh, Summerhall, U.K
| | | | | |
Collapse
|
32
|
Reader TA, Grondin L, Montreuil B, Dewar KM. Dopamine D1 receptors labelled with [3H]SCH23390 in rabbit cerebral cortex and neostriatum. Equilibrium binding, kinetics and selectivity. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 1989; 340:617-25. [PMID: 2575710 DOI: 10.1007/bf00717736] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The binding characteristics of the novel benzazepine compound SCH23390 were studied using membrane preparations from rabbit cerebral cortex (CTX) and neostriatum (CPU; caudate putamen). The association kinetics of [3H]SCH23390 to membranes from CTX and CPU were rapid, while the dissociation kinetics were extremely slow and only around 40-60% of the binding was displaced two hours after the addition of either S(+)-butaclamol or 30 volumes of buffer. The saturation curves revealed that [3H]SCH23390 bound with high affinity in both tissues, with densities of 133 fmol/mg protein for CTX (Kd 25 degrees C = 0.31 nM) and 664 fmol/mg protein for CPU (Kd = 0.13 nM). the specificity of binding to the cortical D1 receptor was verified in competition experiments with a variety of dopaminergic agents. The rank order of potency of these compounds was consistent with the pharmacology of the dopaminergic D1 site. All competition curves were better fitted to a one-site model with Hill coefficients around one, indicating that [3H]SCH23390 was binding to a single cortical site. The stereoselectivity of the cortical [3H]SCH23390 binding site could be demonstrated by the use of enantiomer pairs of dopaminergic drugs. This study provides compelling evidence that [3H]SCH23390 binds to dopamine D1 receptors in the neostriatum and cerebral cortex of the rabbit.
Collapse
Affiliation(s)
- T A Reader
- Département de Physiologie, Faculté de Médecine, Université de Montréal, Québec, Canada
| | | | | | | |
Collapse
|
33
|
Jackson DM, Ross SB, Larsson LG. Dopamine D-2 receptor agonist-induced behavioural depression: critical dependence upon postsynaptic dopamine D-1 function. A behavioural and biochemical study. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 1989; 340:355-65. [PMID: 2573842 DOI: 10.1007/bf00167035] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The dopamine (DA) D-2 receptor agonists quinpirole (threshold dose, 0.01 mg/kg IP), pergolide (0.025 mg/kg), B-HT 920 (0.003 mg/kg) and (-)-3-PPP (4 mg/kg) produced dose-dependent locomotor depression (immobility) in mice as assessed by a subjective scoring system, with the immobility being characterized by a frozen posture. The animals were still but had their eyes open. The immobility was accompanied by reductions in sniffing, rearing and grooming. The depression (and the associated reduction in the various behaviours) produced by quinpirole (0.1 mg/kg), pergolide (0.1 mg/kg) and B-HT 920 (0.1 mg/kg) was substantially (but not always completely) reversed by the selective D-1 receptor agonist SKF38393 (up to 12 mg/kg) and the non-selective D-1 receptor agonist CY208243 (up to 3 mg/kg). The immobility induced by (-)-3-PPP (16 mg/kg) was also reversed by CY208243 and SKF38393, but the reversal was due to an increase in grooming behaviour in mice challenged with the D-1 receptor agonists, whether or not the animals had also received (-)-3-PPP. There was no reversal of the depression of rearing or sniffing. In contrast, CY208243 and SKF38393 also antagonized the immobility induced by B-HT 920, but the reversal was accompanied by at least partial reversals of the depression of sniffing, rearing and grooming. The reversal of quinpirole-induced immobility by SKF38393 and CY208243 was antagonized by SCH23390 (0.1 mg/kg). The selective D-2 receptor antagonist raclopride (0.025 to 0.4 mg/kg) could not reverse quinpirole-induced immobility. High doses of either raclopride (0.4 mg/kg) or SCH23390 (greater than 0.1 mg/kg) significantly increased immobility. Although raclopride itself (0.2 mg/kg) produced a substantial increase in DOPAC and homovanillic acid (HVA) levels in the striatum, it did not antagonize the autoreceptor mediated effects of quinpirole (0.1 mg/kg) in reducing the striatal dihydroxyphenylacetic acid (DOPAC) to DA ratio. However, the same dose of raclopride was partly effective in reducing the effects of lower doses of quinpirole (0.01 and 0.03 mg/kg) on the striatal DOPAC to DA ratio. Raclopride (0.2 mg/kg) also partially but significantly reduced the locomotor stimulant effects of d-amphetamine in reserpinized mice. Biochemical analyses in the striata indicated that CY208243 slightly retarded DA turnover (as assessed by the DOPAC/DA ratio). SKF38393 itself also slightly reduced DA turnover. In automated activity cages, using mice depleted of DA with reserpine and alpha-methyltyrosine, all the D-2 receptor agonists tested, in combination with SKF38393, produced an increase in activity.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
|
34
|
Koda H, Hashimoto T, Kuriyama K. Muscarinic receptor-mediated regulation of OM-853-enhanced dopamine release in striatum of rat. Eur J Pharmacol 1989; 162:501-8. [PMID: 2744083 DOI: 10.1016/0014-2999(89)90341-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The effect of OM-853, a new vincamine analogue, on cerebral dopaminergic neurons was investigated in male Wistar rats. The administration of OM-853 (200 mg/kg p.o.) induced facilitation of the metabolic turnover of dopamine (DA) in all brain areas except the cerebral cortex. Addition of OM-853 enhanced the release of [3H]DA from striatal slices; this release was antagonized by atropine (10(-7) M). However, pretreatment with scopolamine (0.5 mg/kg s.c.) inhibited the enhancement of striatal DA turnover induced by OM-853 administration. OM-853 (10(-4) M) inhibited [3H]quinuclidinyl benzilate binding to muscarinic cholinergic receptors in a striatal particulate fraction more potently than carbachol (10(-4) M). These results suggest that OM-853 may induce facilitation of striatal DA turnover by enhancing DA release via the stimulation of muscarinic cholinergic receptor.
Collapse
Affiliation(s)
- H Koda
- Department of Pharmacology, Kyoto Prefectural University of Medicine, Japan
| | | | | |
Collapse
|
35
|
Ståhle L, Ungerstedt U. On the selectivity and specificity of the antagonism of apomorphine-induced suppression of exploration by sulpiride. Psychopharmacology (Berl) 1989; 99:75-9. [PMID: 2528780 DOI: 10.1007/bf00634456] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Ten behavioural variables were recorded by means of an automatic holeboard apparatus. The behaviour of rats placed for the first time in the apparatus was recorded for 10 min. The suppression of this exploratory behaviour by the dopamine agonist apomorphine (0.01-0.1 mg/kg) was shown to be reversible in a surmountable fashion by the dopamine antagonist sulpiride (2 and 4 mg/kg). Suppression of exploration induced by clonidine (0.05-0.2 mg/kg) or diazepam (2 mg/kg) was not antagonised by sulpiride (10 and 50 mg/kg, respectively). The partial dopamine D1-agonist SKF 38393 (2-20 mg/kg) also suppressed exploration but neither sulpiride (20 mg/kg) nor the D1-antagonist SCH 23390 (0.02 mg/kg) could antagonise this effect. The data show that dopamine agonist induced suppression of exploration display pharmacological characteristics of a receptor-mediated response and the data support our previous suggestion that these receptors may be pharmacologically distinct from other dopamine D2-receptors.
Collapse
Affiliation(s)
- L Ståhle
- Department of Pharmacology, Karolinska Institutet, Stockholm, Sweden
| | | |
Collapse
|
36
|
Temlett JA, Quinn NP, Jenner PG, Marsden CD, Pourcher E, Bonnet AM, Agid Y, Markstein R, Lataste X. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Mov Disord 1989; 4:261-5. [PMID: 2571082 DOI: 10.1002/mds.870040307] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
The effect of stimulation of cerebral dopamine D-1 receptors by CY 208-243 on motor disability was tested in MPTP-treated parkinsonian marmosets and patients with Parkinson's disease. CY 208-243 (0.5-1.25 mg/kg s.c.) produced a dose-related reversal of akinesia and rigidity in the marmosets, lasting some 2 h. Single morning doses of CY 208-243 (5-40 mg) were compared with the usual morning dose of levodopa in eight patients with Parkinson's disease on long-term levodopa therapy who had developed motor fluctuations from immobility with akinesia and rigidity (off) to mobility often with dyskinesias (on). CY 208-243 alone was capable of switching such patients from off to on; five of the eight patients responded to the highest dose (40 mg), sometimes with dyskinesias. The response to CY 208-243 was comparable to that produced by levodopa in these cases. Drugs designed to stimulate both dopamine D1 and D2 receptors in the brain may improve the therapy of Parkinson's disease.
Collapse
Affiliation(s)
- J A Temlett
- University Department of Neurology, Queen Square, London, England
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Jeziorski M, White FJ. Dopamine agonists at repeated "autoreceptor-selective" doses: effects upon the sensitivity of A10 dopamine autoreceptors. Synapse 1989; 4:267-80. [PMID: 2603146 DOI: 10.1002/syn.890040403] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Previous reports have established the ability of dopamine (DA) agonists to stimulate inhibitory DA autoreceptors at doses which minimally stimulate postsynaptic DA receptors, suggesting that hyperactive DA transmission may be controlled clinically by treatment with DA agonists. Little is known, however, about the possible loss of autoreceptor sensitivity that may occur after repeated treatment with low doses of DA agonists. Extracellular single cell recording and microiontophoretic techniques were used to measure the sensitivity of impulse-regulating DA autoreceptors on A10 DA cells in the ventral tegmental area (VTA) of chloral hydrate-anesthetized rats pretreated for seven days with repeated subcutaneous (s.c.) doses of the DA agonist apomorphine (APO). The ability of intravenous (i.v.) administration of the potent D2 DA agonist quinpirole (QUIN) to inhibit the firing of A10 cells was not attenuated in rats pretreated with repeated low doses (2 x 50 micrograms/kg/day, s.c.) of APO for 7 days, although higher doses (2 x 250 or 500 micrograms/kg/day) did cause subsensitive responses to QUIN. In rats pretreated with repeated low doses of APO, microiontophoretic application of DA on A10 cells revealed somewhat subsensitive responses. However, ibotenic acid lesions of postsynaptic cells in the nucleus accumbens (NAc) prior to initiation of APO treatment (2 x 50 micrograms/kg/day) did not alter the response of A10 cells to systemic QUIN, contradicting the possibility that the feedback projection from the NAc to the VTA was compensating for autoreceptor down-regulation during systemic challenge with QUIN. In contrast, administration of the irreversible DA antagonist EEDQ (2 mg/kg, i.p.) to control and APO-treated rats (2 x 50 micrograms/kg/day) 24 hr prior to recording did reveal a difference in A10 cell sensitivity to systemic QUIN and to microiontophoretic DA between the two groups, suggesting that "spare" DA autoreceptors may have concealed the down-regulation of autoreceptors induced by repeated low doses of APO. Challenge of A10 DA cells with the partial DA autoreceptor agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine [(-)3-PPP], for which an autoreceptor reserve should not exist, produced slightly attenuated responses in APO-treated rats (2 x 50 micrograms/kg/day). These findings provide evidence for the existence of spare somatodendritic DA autoreceptors on A10 DA cells with respect to potent DA agonists, suggesting that repeated administration of "autoreceptor-selective" doses of DA agonists may not result in a diminished inhibition of DA neuronal activity.
Collapse
Affiliation(s)
- M Jeziorski
- Wayne State University, Department of Psychiatry, Detroit, Michigan
| | | |
Collapse
|
38
|
Mayer A, Limberger N, Starke K. Transmitter release patterns of noradrenergic, dopaminergic and cholinergic axons in rabbit brain slices during short pulse trains, and the operation of presynaptic autoreceptors. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 1988; 338:632-43. [PMID: 2907613 DOI: 10.1007/bf00165627] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Slices of rabbit brain were field-stimulated either by single electrical pulses or by trains of 4 or 8 pulses at 1 or 100 Hz in order to study transmitter release patterns and the autoinhibition of transmitter release. The slices were preincubated with 3H-noradrenaline (cortex), 3H-dopamine (caudate nucleus) or 3H-choline (caudate nucleus). Slices preincubated with 3H-noradrenaline were superfused with medium containing desipramine 1 mumol/l. The overflow of tritium elicited by single pulses amounted to 0.19% of the tritium content of the tissue. The overflow elicited by 4 pulses/1 Hz was similar, whereas that elicited by 4 pulses/100 Hz was 5.1-fold higher. Yohimbine 10-1000 nmol/l increased up to 2.5-fold the overflow evoked by 4 pulses/1 Hz but did not change the overflow evoked by single pulses or 4 pulses/100 Hz. - Slices preincubated with 3H-dopamine were superfused with medium containing nomifensine 1 mumol/l. The overflow of tritium elicited by single pulses was 0.39% of the tritium content of the tissue. The overflow elicited by 4 pulses/1 Hz was 1.3-fold and the overflow elicited by 4 pulses/100 Hz 1.4-fold higher. Domperidone 1-100 nmol/l and sulpiride 10-1000 nmol/l increased up to 2.4-fold the overflow evoked by 4 pulses/1 Hz but increased only slightly the overflow evoked by single pulses or 4 pulses/100 Hz. - Slices preincubated with 3H-choline were superfused either with physostigmine-free medium or with medium containing physostigmine 1 mumol/l. In physostigmine-free medium, atropine did not increase the evoked overflow of tritium at any stimulation condition. In physostigmine-containing medium, the overflow elicited by single pulses was 0.18% of the tritium content of the tissue. The overflow elicited by 8 pulses/1 Hz was 2.0-fold and the overflow elicited by 8 pulses/100 Hz 2.2-fold higher. Atropine 2-200 nmol/l increased up to 2.4-fold the overflow evoked by 8 pulses/1 Hz but increased only slightly the overflow evoked by single pulses or 8 pulses/100 Hz. In physostigmine-free medium, sulpiride 10-1000 nmol/l did not change the single-pulse-evoked overflow of tritium in the absence but increased it in the presence of nomifensine 1 mumol/l. Single pulses elicit a large release of 3H-noradrenaline, 3H-dopamine and 3H-acetylcholine under the conditions of these experiments. Release elicited by single pulses is not subject to autoinhibition except for a small inhibition by spontaneously released transmitter in the case of dopaminergic and cholinergic axons.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- A Mayer
- Pharmakologisches Institut der Universität, Freiburg i. Br., Federal Republic of Germany
| | | | | |
Collapse
|
39
|
Markstein R, Emson P. Effect of neurotensin and its fragments neurotensin-(1-6) and neurotensin-(8-13) on dopamine release from cat striatum. Eur J Pharmacol 1988; 152:147-52. [PMID: 3208829 DOI: 10.1016/0014-2999(88)90846-1] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
At low concentrations, neurotensin (10(-9) M) enhanced electrically evoked release of dopamine. At higher concentrations, neurotensin (10(-7) M) also enhanced basal release of dopamine. The carboxy-terminal sequence of neurotensin-(8-13) was fully active and enhanced both electrically evoked and basal release. In contrast, the amino-terminal fragment neurotensin-(1-6) did not enhance electrically evoked release of dopamine even at high concentrations (10(-6) M). However, it retained the ability to enhance basal dopamine release. Combination of different doses of apomorphine with a subthreshold (10(-10) M) and submaximal concentrations (10(-9) M) of neurotensin gave clear additive effects. It is concluded that in the cat striatum neurotensin stimulates dopamine release by a direct effect on its own neurotensin receptor, and does not modulate the sensitivity of presynaptic dopamine autoreceptors. Furthermore, it is suggested that there exist at least two types of neurotensin receptors in the cat striatum. One type stimulates evoked dopamine release and another influences basal release of dopamine.
Collapse
Affiliation(s)
- R Markstein
- Preclinical Research, Sandoz Ltd., Basle, Switzerland
| | | |
Collapse
|
40
|
COMMUNICATIONS. Br J Pharmacol 1988. [DOI: 10.1111/j.1476-5381.1988.tb16609.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
41
|
Arnt J, Bøgesø KP, Hyttel J, Meier E. Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. PHARMACOLOGY & TOXICOLOGY 1988; 62:121-30. [PMID: 3259694 DOI: 10.1111/j.1600-0773.1988.tb01859.x] [Citation(s) in RCA: 101] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The effects of a range of dopamine (DA) agonists on stereotyped behaviour in rats were analysed and compared both with the affinity of the compounds for D1 and D2 receptor binding sites in vitro and their ability to stimulate the adenylate cyclase activity in rat striatal homogenates. Full and partial agonists at the D1 receptor coupled to adenylate cyclase do not induce sterotypies when given alone, whereas full D2 agonists (e.g. quinpirole) induce hyperactivity but not oral sterotypies. Partial D2 agonists (e.g. (-)-3-PPP) only induce sedation. Mixed D1/D2 agonists (e.g. apomorphine) induce both hyperactivity and oral stereotypies. Maximum stereotypies were induced by combination of SK & F 38393 and a series of D2 agonists, including full agonists and the partial D2 agonist B-HT 920, whereas partial agonists with low intrinsic activity (e.g. (-)-3-PPP, EMD 23448) did not induce stereotypies when given together with SK & F 38393. However, these partial agonists reduced the maximum effect of apomorphine, whereas the full agonists (e.g. quinpirole, (-)-NPA) and B-HT 920 had no apomorphine antagonistic activity. The mixed D1/D2 agonists apomorphine and N,N-dipropyl-5,6-ADTN were only weakly influenced by SK & F 38393, or not at all. D1 agonists with central effects, including SK & F 38393, SK & F 81297 (with relatively high efficacies), and the partial agonist SK & F 75670 with low efficacy, changed the hyperactivity induced by quinpirole into maximum oral stereotypy, whereas the peripheral D1 agonist fenoldopam had no such effect. Inhibition of DA and NA synthesis with alpha-methyl-p-tyrosine depleted striatal DA levels by 72 per cent and antagonized the hyperactivity induced by the D2 agonists quinpirole and (-)-NPA, but not that of apomorphine. Combination of SK & F 38393 and quinpirole induced maximum stereotypy in DA-depleted animals. These results suggest that D1 receptor tonus is a necessary prerequisite for the expression of a DA agonist's effect. The hyperactivity induced by full D2 agonists appears to be mediated by D1 tonus provided by endogenous DA activity, but stronger D1 stimulation is necessary to induce oral stereotypy. A high degree of D1 receptor activation increases the ability of partial D2 agonists to induce hyperactivity or oral stereotypies since treatment with both SK & F 38393 and B-HT 920 had marked effects while B-HT 920 was ineffective.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- J Arnt
- Research Laboratories, H. Lundbeck A/S, Valby, Denmark
| | | | | | | |
Collapse
|
42
|
Van der Weide J, De Vries JB, Tepper PG, Krause DN, Dubocovich ML, Horn AS. N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models. Eur J Pharmacol 1988; 147:249-58. [PMID: 3130270 DOI: 10.1016/0014-2999(88)90783-2] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The selectivity of the potent dopamine D-2 agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0437) was examined in a series of in vivo and in vitro pharmacological models. In radioligand binding assays, N-0437 showed high potency (Ki = 0.69 nM) and selectivity for D-2 receptors as compared to its potency and selectivity at various other neuronal receptors (Ki in nM): D-1 (678) dopamine, alpha 1-(534) and alpha 2-(195) adrenoceptor, S1-(6940) and S2-(5900) serotonin and muscarine (2660). Very low activity (Ki greater than 10(-5) M) was seen at the beta-adrenoceptor, A1-adenosine, GABAA and benzodiazepine receptors. Furthermore, N-0437 inhibited the calcium-dependent release of [3H]dopamine (IC50: 4 nM) and [3H]acetylcholine (IC50: 6.3 nM) from rabbit striatal slices in the nanomolar range. These effects of N-0437 were mediated through activation of D-2 dopamine autoreceptors and D-2 dopamine heteroreceptors, respectively. Presynaptic dopaminergic activity in vivo was measurable as an inhibition of the locomotor activity of mice, and in this model N-0437 was more effective than apomorphine. Moreover, the effect of N-0437 could be antagonized by sulpiride but not by yohimbine. N-0437 was equipotent with apomorphine in inducing circling behaviour in 6-OHDA-lesioned rats. N-0437 had almost no serotonergic activity in vivo. The results show that N-0437 is a selective dopamine D-2 agonist, and thus, that it is a new ligand of choice for studies on the D-2 receptor.
Collapse
Affiliation(s)
- J Van der Weide
- Department of Medicinal Chemistry, State University of Groningen, The Netherlands
| | | | | | | | | | | |
Collapse
|
43
|
Filloux F, Liu TH, Hsu CY, Hunt MA, Wamsley JK. Selective cortical infarction reduces [3H]sulpiride binding in rat caudate-putamen: autoradiographic evidence for presynaptic D2 receptors on corticostriate terminals. Synapse 1988; 2:521-31. [PMID: 2973146 DOI: 10.1002/syn.890020508] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Although the existence of presynaptic D2 dopamine receptors on corticostriate terminals has been supported by numerous receptor-binding studies, recent autoradiographic data has failed to demonstrate loss of striatal D2 receptors following cortical lesions. In the present study, Long-Evans rats were subjected to unilateral middle cerebral artery (MCA) infarction in order to produce reproducible lesions of the neocortex without damaging subcortical structures. Animals were sacrificed 2 and 4 wk following lesion and brains were prepared for receptor autoradiography. D2 receptors were studied using the selective ligand [3H]sulpiride, while D1 dopamine receptors were examined using [3H]SCH 23390. Sodium-dependent, high-affinity choline uptake sites were labeled with [3H]hemicholinium-3, thereby providing a quantitative measure of cholinergic neuronal integrity. Unilateral cortical infarction resulted in approximately a 20% reduction in [3H]sulpiride binding in several discrete regions of the ipsilateral caudate-putamen (CPu), but not in the nucleus accumbens. D2 receptor binding was also reduced significantly in some areas of the contralateral CPu when compared with [3H]sulpiride binding in sham-operated, control animals. In contrast, D1 receptors (as identified by [3H]SCH 23390 and high-affinity choline uptake sites (labeled with [3H]-HC-3) were not affected by the cortical lesion. The results provide autoradiographic confirmation of the existence of presynaptic D2 receptors on corticostriate terminals.
Collapse
Affiliation(s)
- F Filloux
- Department of Psychiatry, University of Utah School of Medicine, Salt Lake City 84132
| | | | | | | | | |
Collapse
|
44
|
Mulder TB, de Vries JB, Dijkstra D, Wiechers JW, Grol CJ, Horn AS. Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 1987; 336:494-501. [PMID: 2830544 DOI: 10.1007/bf00169305] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The in vitro binding of the putative dopamine autoreceptor agonist [3H]DP-7-ATN to rat striatal membrane homogenates was investigated. The maximum number of binding sites Bmax was 497.5 +/- 50.2 fmol/mg protein and the affinity constant KD was 8.3 +/- 1.5 nM using 10 microM (+) butaclamol to define non-specific binding. Lesion of the left medium forebrain bundle by 6-hydroxydopamine resulted in an almost complete loss of dopamine in the striatum but did not affect the binding of [3H]DP-7-ATN. The binding of [3H]DP-7-ATN to the homogenates of the dopaminergic cell bodies in the substantia nigra revealed a Bmax of 542.4 +/- 40.1 fmol/mg protein and a KD of 11.1 +/- 1.3 nM. The pharmacological profile of the binding was characterized as being to D-2 receptors. No direct in vitro evidence could be found for a selective binding to DA autoreceptors. The dopamine uptake inhibitor GBR 12909 interacted in a noncompetitive manner with the in vitro binding of [3H]DP-7-ATN and the latter compounds uptake into isolated synaptosomes was not through the specific dopamine uptake system but rather through diffusion. GBR 12909 failed to reveal any agonistic or antagonistic activity in the GBL model but was able to antagonize the hypomotility in rats induced by 0.25 mg/kg DP-7-ATN. The inhibitory effect of DP-7-ATN on DA release was also demonstrated using in vivo brain dialysis in conscious rats. Based on the above results, the possibility is discussed that the release regulating DA autoreceptors, which might be coupled to the reuptake complex, and the DA biosynthesis regulating autoreceptors, are different entities.
Collapse
Affiliation(s)
- T B Mulder
- Department of Medicinal Chemistry, State University Groningen, The Netherlands
| | | | | | | | | | | |
Collapse
|
45
|
Abstract
1. In isolated perfused rat liver, the effects of alpha-adrenergic stimulation by phenylephrine (2 microM), such as an increase of portal pressure, glucose output, Ca2+ release into the perfusate and the characteristic K+ flux changes across the hepatocyte plasma membrane were almost completely abolished in the presence of amiloride (0.5 mM). 2. When the phenylephrine concentration was raised to about 100 microM, the effects of the alpha-adrenergic agonist on hepatic metabolism, Ca2+ and K+ fluxes, but not on the portal venous pressure, were restored, suggesting a competitive antagonism by amiloride. 3. Amiloride antagonized in a concentration-dependent manner noradrenaline-induced isometric contractions of strips of the rabbit pulmonary artery. The concentration-response curve of noradrenaline was shifted to the right, and the maximal response obtained was also depressed, suggesting a mixed competitive and non-competitive antagonism. The estimated amiloride-adrenoceptor-dissociation constant was 8 microM. 4. The affinity of amiloride to the alpha- and beta-adrenoceptor subtypes was determined by radioligand binding assays using [125I]BE 2254 binding to rat liver plasma membranes (alpha 1-subtype), [3H]yohimbine binding to human platelet membranes (alpha 2-subtype), (-)-[125I]iodocyanopindolol (ICYP) binding to rabbit lung membranes in presence of the beta 2-adrenoceptor antagonist ICI 118,551 (beta 1-subtype) and ICYP binding to rat lung membranes in presence of the beta 1-blocker atenolol (beta 2-subtype). In all systems, amiloride inhibited specific ligand binding concentration-dependently, the Ki values for amiloride were about 25, 52, 148 and 161 microM for alpha 1- alpha 2-, beta 1- and beta 2-adrenoceptor subtypes, respectively. 5. It is concluded that amiloride in concentrations below those required for inhibition of the Na+/H+ exchanger is a potent antagonist of alpha- and beta-adrenoceptors in a variety of experimental systems. Whether the adrenergic antagonism of amiloride is important for antihypertensive therapy, remains to be elucidated.
Collapse
Affiliation(s)
- D Häussinger
- Medizinische Universitätsklinik Freiburg, Federal Republic of Germany
| | | | | |
Collapse
|
46
|
Markstein R, Enz A, Vigouret JM, Jaton A, Closse A, Briner U, Gull P. Biochemical, behavioural, and endocrine effects of CK 204-933, a novel 8 beta-ergolene. J Neural Transm (Vienna) 1987; 69:179-99. [PMID: 2887630 DOI: 10.1007/bf01244340] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
CK 204-933 displaces [3H]dopamine and [3H]spiperone with high affinity from D-1 and D-2 recognition sites in membranes of calf caudate. Results from functional in vitro tests suggest that it is a partial agonist at D-1 receptors and an antagonist at D-2 receptors. These opposite effects at dopamine receptor subtypes are also expressed in vivo. For instance, in 6-hydroxydopamine lesioned rats, CK 204-933 induces contralateral rotations which are antagonised by SCH 23390 but not by sulpiride. On the other hand, CK 204-933 induces a long lasting increase of dopamine turnover in rat striatum and antagonises apomorphine-induced gnawing behaviour in rats. CK 204-933 increases prolactin serum levels in rats after subcutaneous administration, whereas after oral administration a moderate decrease of prolactin serum levels was seen. The latter effect is probably due to the formation of active metabolites. CK 204-933 exhibits also a high affinity to [3H]prazosin binding sites and antagonises serotonin-mediated stimulation of adenylate cyclase in rat hippocampus. On the other hand, CK 204-933 has no effect of only very weak effects on noradrenaline and serotonin release from rat cerebral cortex slices, which is consistent with its weak effects on noradrenaline- and serotonin-turnover in rat brain. Based on these properties it is suggested that CK 204-933 could be of therapeutic value in brain diseases associated with disturbances of monoaminergic neurotransmission.
Collapse
MESH Headings
- Animals
- Behavior, Animal/drug effects
- Binding, Competitive
- Brain/drug effects
- Brain/metabolism
- Brain/physiology
- Cattle
- Cyclic AMP/metabolism
- Dopamine/metabolism
- Dopamine Antagonists
- Ergolines/metabolism
- Ergolines/pharmacology
- In Vitro Techniques
- Male
- Neurotransmitter Agents/metabolism
- Norepinephrine/metabolism
- Prolactin/blood
- Rats
- Receptors, Adrenergic, alpha/drug effects
- Receptors, Adrenergic, alpha/metabolism
- Receptors, Dopamine/drug effects
- Receptors, Dopamine/metabolism
- Receptors, Serotonin/drug effects
- Receptors, Serotonin/metabolism
- Retina/drug effects
- Serotonin/metabolism
- Substantia Nigra/drug effects
- Substantia Nigra/physiology
Collapse
|
47
|
|
48
|
Herdon H, Strupish J, Nahorski SR. Endogenous dopamine release from rat striatal slices and its regulation by D-2 autoreceptors: effects of uptake inhibitors and synthesis inhibition. Eur J Pharmacol 1987; 138:69-76. [PMID: 3622608 DOI: 10.1016/0014-2999(87)90338-4] [Citation(s) in RCA: 35] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The effects of various dopaminergic drugs on the spontaneous and veratrine-stimulated release of endogenous dopamine (DA) from superfused rat striatal slices have been examined using a high-sensitivity HPLC system. The DA uptake inhibitor nomifensine greatly increased both veratrine-stimulated and spontaneous DA release, whilst the effects of the more potent and selective inhibitor GBR 12921 were much smaller. The DA agonists pergolide and LY 171555 reduced both spontaneous and veratrine-stimulated DA release; conversely, the D-2 selective antagonist l-sulpiride stereospecifically increased spontaneous and veratrine-stimulated release, and blocked the effects of pergolide and LY 171555. Inhibition of DA synthesis did not directly influence the actions of either pergolide or sulpiride. These studies indicate that nomifensine may have a DA-releasing action in addition to its uptake blocking action, the regulation of endogenous DA release by D-2 autoreceptors shows properties similar to those reported previously for radiolabelled DA release, with the novel finding that spontaneous release is also regulated, the autoreceptors do not appear to selectively influence newly synthesised DA release.
Collapse
|
49
|
Sabol B, Boldry R, Farooqui T, Chang YA, Miller D, Uretsky N. Effect of permanently charged and uncharged dopaminergic agonists on the potassium-induced release of [3H]acetylcholine from striatal slices. Biochem Pharmacol 1987; 36:1679-85. [PMID: 3109428 DOI: 10.1016/0006-2952(87)90054-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The effects of chemical analogs of dopamine, which are permanently charged or which lack a net positive charge, on the potassium-evoked release of [3H]acetylcholine from mouse striatal slices were studied in order to determine whether a positive charge on the dopamine agonist molecule is required to activate dopaminergic receptors. The striatal slices were first preincubated with [3H]choline, transferred to a superfusion chamber, and then superfused in physiological medium. [3H]Acetylcholine release was evoked by exposure of the slices to a high potassium medium and potential dopamine agonist drugs were added to the medium 10 min before superfusing with high potassium. A permanently charged quaternary ammonium analog and dimethylselenonium analog of dopamine inhibited the potassium-evoked release of [3H]acetylcholine, and this inhibition was antagonized by sulpiride, a dopamine receptor antagonist. However, this inhibition was not antagonized by reserpine and alpha-methyl-p-tyrosine, which was shown to completely antagonize the inhibitory effect of amphetamine, an indirectly acting amine. This suggests that the charged dopamine analogs are acting directly on dopaminergic receptors. In contrast to the permanently charged dopamine analogs, analogs of dopamine with no net positive charge produced no inhibition of the potassium-evoked [3H]acetylcholine release. These in vitro observations are in agreement with a behavioral model in which a permanently uncharged monomethylsulfide analog of dopamine was ineffective in eliciting circling behavior after its unilateral injection into the striatum of rats in which dopamine neurons were previously lesioned by the injection of 6-hydroxydopamine into the medial forebrain bundle. In contrast, under these same conditions, the intrastriatal injection of the charged quaternary ammonium or dimethylsulfonium analog of dopamine elicited intense contralateral circling. These results suggest that the charged form of a dopamine agonist molecule is required to bind to and activate the dopamine receptor regulating [3H]acetylcholine release and circling behavior.
Collapse
|
50
|
Weick BG, Walters JR. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses. Brain Res 1987; 405:234-46. [PMID: 2952219 DOI: 10.1016/0006-8993(87)90293-9] [Citation(s) in RCA: 131] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Extracellular single unit recording techniques were used to compare the effects of selective and non-selective dopamine agonists on substantia nigra pars reticulata activity in rats with 6-hydroxydopamine induced lesions of the nigrostriatal dopamine pathway. As previously shown, apomorphine (0.32 mg/kg), a dopamine agonist that interacts with both D1 and D2 dopamine receptor subtypes, produced consistent inhibitions of substantia nigra pars reticulata activity in these animals. The D1-receptor agonist, SKF 38393 (RS-SKF 38393, 10 mg/kg), also induced significant inhibitions in the activity of these neurons in 6-hydroxydopamine lesioned rats, although less consistently than did apomorphine. The effects of SKF 38393 were reversed by the D1-antagonist, SCH 23390. The D2 selective agonist quinpirole was considerably less effective than apomorphine at inhibiting substantia nigra pars reticulata activity at doses up to 1 mg/kg. Since comparable experiments have shown that quinpirole is as effective as apomorphine at producing dopamine D2-autoreceptor-mediated effects on dopamine neuron activity, quinpirole's lack of efficacy in the present study relative to that of apomorphine does not appear to be related to differences in relative potency for central D2-receptors using this route of administration. Rather, the relative effectiveness of SKF 38393 on pars reticulata activity suggests that selective stimulation of D1-receptors is at least, if not more, efficacious than selective stimulation of D2-receptors at inducing alterations in the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats. The simultaneous stimulation of both receptors, however, was considerably more effective than selective stimulation of either receptor subtype: doses of SKF 38393 and quinpirole which had no significant effect on nigral activity when administered alone brought about marked inhibition of the firing of these cells when administered simultaneously. No such inhibition was seen when the inactive enantiomer, S-SKF 38393, was substituted for the racemic form of SKF 38393 in this protocol. These observations in 6-hydroxydopamine lesioned rats support other recent findings indicating that the two dopamine receptor subtypes can interact in a synergistic way to affect basal ganglia output.
Collapse
|